Natera, Inc. (NTRA) Upgraded to “Hold” at Zacks Investment Research
Zacks Investment Research upgraded shares of Natera, Inc. (NASDAQ:NTRA) from a sell rating to a hold rating in a research report sent to investors on Friday morning.
According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “
NTRA has been the topic of a number of other reports. ValuEngine cut Natera from a sell rating to a strong sell rating in a research note on Monday, July 24th. BidaskClub cut Natera from a hold rating to a sell rating in a research note on Tuesday, August 1st. Morgan Stanley reduced their target price on Natera from $18.00 to $13.00 and set an overweight rating on the stock in a research note on Monday, August 7th. Finally, Cowen and Company reissued a buy rating and set a $14.00 target price on shares of Natera in a research note on Friday, September 1st. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of $14.45.
Natera (NASDAQ NTRA) traded up 2.47% during mid-day trading on Friday, reaching $12.46. 149,356 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $13.02 and a 200-day moving average of $13.02. Natera has a one year low of $7.88 and a one year high of $13.49. The stock’s market cap is $663.16 million.
Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, August 8th. The medical research company reported ($0.52) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.52). The business had revenue of $53.60 million for the quarter, compared to analysts’ expectations of $50.57 million. Natera had a negative return on equity of 137.46% and a negative net margin of 62.64%. The business’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.46) EPS. On average, equities research analysts anticipate that Natera will post ($2.03) earnings per share for the current year.
WARNING: This story was published by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/09/23/natera-inc-ntra-upgraded-to-hold-at-zacks-investment-research.html.
In other Natera news, insider Jonathan Sheena sold 120,000 shares of the business’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $12.54, for a total value of $1,504,800.00. Following the sale, the insider now directly owns 533,208 shares of the company’s stock, valued at $6,686,428.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.57% of the stock is owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in NTRA. Virtu KCG Holdings LLC bought a new stake in Natera in the second quarter worth $126,000. American International Group Inc. boosted its holdings in Natera by 7.1% in the first quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock worth $142,000 after acquiring an additional 1,068 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Natera by 1.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 16,118 shares of the medical research company’s stock worth $143,000 after acquiring an additional 194 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Natera in the second quarter worth $151,000. Finally, Goldman Sachs Group Inc. boosted its holdings in Natera by 45.3% in the first quarter. Goldman Sachs Group Inc. now owns 17,386 shares of the medical research company’s stock worth $154,000 after acquiring an additional 5,417 shares in the last quarter. 59.79% of the stock is currently owned by institutional investors and hedge funds.
Natera Company Profile
Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.